Five-Year ZUMA-5 Data Shows Axicabtagene Ciloleucel Achieves Durable Responses in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
核心洞察
Axicabtagene ciloleucel demonstrated sustained efficacy with 90% overall response rate and 75% complete response rate in 159 patients with relapsed/refractory indolent non-Hodgkin lymphoma (搜索) after median follow-up of 64.6 months.
Median progression-free survival reached 62.2 months with 5-year rate of 50.4%, while median overall survival was not reached with estimated 5-year rate of 69.0%.
Analysis revealed a plateau in lymphoma-specific progression-free survival after 30 months in follicular lymphoma (搜索) patients, suggesting potential curative therapy with 55% of patients alive without subsequent anticancer therapy.
Axicabtagene ciloleucel (axi-cel) has demonstrated sustained clinical benefits in patients with relapsed or refractory indolent non-Hodgkin lymphoma (搜索), with 5-year follow-up data from the phase II ZUMA-5 trial showing durable responses and potential curative effects, particularly in follicular lymphoma (搜索) patients.
The single-arm, multicenter trial enrolled 159 patients, including 127 with follicular lymphoma (搜索) and 31 with marginal zone lymphoma (搜索), who received lymphodepleting chemotherapy followed by axi-cel at a target dose of 2 × 10⁶ CAR T cells/kg. With a median follow-up of 64.6 months, the therapy achieved an objective response rate of 90%, including complete response in 75% of patients.
Sustained Efficacy and Survival Outcomes
The median duration of response reached 60.4 months, demonstrating the durability of therapeutic benefit. Median progression-free survival among all patients was 62.2 months (95% confidence interval = 34.9 months to not evaluable), with a 5-year rate of 50.4%. For patients with follicular lymphoma (搜索) specifically, median progression-free survival was 57.3 months with a 5-year rate of 49.8%, while patients with marginal zone lymphoma (搜索) showed a 5-year rate of 53.9% with median progression-free survival not reached.
Notably, median overall survival was not reached, with an estimated 5-year rate of 69.0%. At data cutoff, 55% of patients were alive without requiring subsequent anticancer therapy, and median time to next treatment remained not reached with an estimated 5-year rate of 53.3%.
Curative Potential in Follicular Lymphoma
Analysis of lymphoma-specific survival in follicular lymphoma (搜索) patients revealed particularly encouraging findings. The cumulative incidence of progression or death due to lymphoma or study treatment was 34%, with a plateau in lymphoma-specific progression-free survival beginning to emerge after 2 years. Only 2 lymphoma-specific events occurred after month 30 post-infusion, suggesting that patients with follicular lymphoma who remain in remission beyond this point may be functionally cured.
Among patients with follicular lymphoma (搜索), the 5-year lymphoma-specific death rate was 15.6%. The 60-month rate of progression or lymphoma-specific death was 35.1%, while the rate of competing risks was 15.1%.
Biomarker Correlations and Predictive Factors
Correlative analyses identified key factors associated with durable responses. Robust early CAR T-cell expansion and naive product phenotype were associated with durable responses and prolonged survival in patients with follicular lymphoma (搜索). Patients who remained in ongoing response had a naive T-cell frequency of 22.3% compared with 13.5% in those who relapsed and 9.0% in nonresponders.
Long-Term Safety Profile
The 5-year analysis confirmed a manageable safety profile with no new safety signals emerging since the 3-year follow-up. Since the 3-year analysis, 13 patients experienced new adverse events, including one serious event considered related to axi-cel: grade 3 myelodysplastic syndrome (搜索). Six patients (4%) developed second primary malignancies, including acute leukemia (搜索), though none were of T-cell origin and were considered related to lymphodepleting chemotherapy and/or axi-cel.
A total of 46 patients (30%) died during the study, with mortalities evenly split between relapse-related and non-relapse causes.
Clinical Implications and Future Directions
The investigators concluded that these findings confirm sustained responses and manageable safety with axi-cel in the long term among patients with relapsed or refractory indolent non-Hodgkin lymphoma (搜索) and its potential as a curative therapy in follicular lymphoma (搜索).
A phase 3 randomized controlled trial, ZUMA-22, has been initiated to formally compare the benefit of axi-cel against standard-of-care therapies for relapsed/refractory follicular lymphoma (搜索), which will provide definitive evidence for the therapy's role in this patient population.